Impedimed Limited ( (IPDQF) ) has released its Q1 earnings. Here is a breakdown of the information Impedimed Limited presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ImpediMed Limited, a medical technology company specializing in bioimpedance spectroscopy, offers innovative solutions for patient health management, particularly in lymphoedema, heart failure, and body composition. The company’s latest quarterly report reveals a record revenue of A$3.6 million, driven by strong demand for its SOZO Digital Health Platform. Despite a decrease in Total Contracted Value compared to the previous quarter, the company achieved an Annual Recurring Revenue of A$14.4 million, highlighting its resilience amid currency fluctuations. ImpediMed’s strategic initiatives include the launch of SOZO Pro, enhancing its market position and expanding its reach in the US healthcare sector. The company maintains a robust cash balance of A$23.0 million, ensuring continued investment in growth opportunities. Looking ahead, ImpediMed remains focused on expanding its market presence and achieving cash flow break-even, supported by its innovative product offerings and strategic partnerships.